Taft’s Pharmaceutical and Life Sciences Litigation practice was recognized by LMG Life Sciences. The firm was ranked in Tier 2 for Hatch-Waxman Patent Litigation (Generic). Taft Pharma Litigation partners Stephen Auten and Richard Ruzich were also selected for Hatch-Waxman Patent Litigation.
LMG Life Sciences identifies the top law firms and lawyers in each practice area of the life sciences industry. Rankings are based on key criteria of recent case evidence, peer evaluation, and client feedback.
Auten is chair of Taft’s Pharmaceutical and Life Sciences Litigation group. He is a widely recognized and seasoned attorney in Hatch-Waxman and biosimilar matters, including related patent litigation, and is followed by key industry leaders (brand and generic alike), law firms, analysts, educators, and others on his LinkedIn blog, “Hatch Waxman ANDA Litigation Forum,” which has more than 11,000 members worldwide. Auten represents clients primarily in the areas of Paragraph IV design strategies, Hatch-Waxman litigation, and biosimilar market opportunities.
Ruzich is an internationally recognized patent attorney who focuses on complex patent litigation, representing generic pharmaceutical companies in ANDA litigation under the Hatch-Waxman statutory framework. An accomplished trial and appellate advocate, registered patent attorney, and a frequent lecturer and author, he is known worldwide for his legal work on behalf of his generic clients, including biosimilar sponsors. His experience covers the entire lifecycle spectrum from product selection, Paragraph IV development, and through to market entry, including at-risk launches.